ReviewPathogens (Basel, Switzerland)2020
Adaptive Immunity to Dengue Virus: Slippery Slope or Solid Ground for Rational Vaccine Design?
Review in Pathogens (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Potent Cross-Serotype Dengue Neutralization with Low ADE by AG-Strand-Targeting Anti-EDIII Antibodies.ACS omega · 2026Article
- Analytical and Clinical Evaluation of the STANDARD M10 Arbovirus Panel for Dengue Detection, Serotyping, and Multiplex Arboviral Screening in the Americas.Diagnostics (Basel, Switzerland) · 2026Article
- Advances in anti-dengue virus properties of Traditional Chinese Medicines.Frontiers in microbiology · 2026Review
- Review
- An Engineered N-Glycosylated Dengue Envelope Protein Domain III Facilitates Epitope-Directed Selection of Potently Neutralizing and Minimally Enhancing Antibodies.ACS infectious diseases · 2024Article
- Occupational exposure to malaria, leishmaniasis and arbovirus vectors in endemic regions: A systematic review.Current research in parasitology & vector-borne diseases · 2024Review
- Neutralizing antibodies targeting a novel epitope on envelope protein exhibited broad protection against flavivirus without risk of disease enhancement.Journal of biomedical science · 2023Article
- Article
- Induction of humoral and cell-mediated immunity to the NS1 protein of TBEV with recombinant Influenza virus and MVA affords partial protection against lethal TBEV infection in mice.Frontiers in immunology · 2023Article
- Unique cellular immune signatures of multisystem inflammatory syndrome in children.PLoS pathogens · 2022Observational
- Dengue Vaccines: An Update.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022Review
- Host immunity and vaccine development against Dengue virus.Infectious medicine · 2022Review
- Current status and perspectives on vaccine development against dengue virus infection.Journal of microbiology (Seoul, Korea) · 2022Review
- Tick-Borne Encephalitis Virus: A Quest for Better Vaccines against a Virus on the Rise.Vaccines · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The four serotypes of dengue virus are the most widespread causes of arboviral disease, currently placing half of the human population at risk of infection. Pre-existing immunity to one dengue virus serotype can predispose to severe disease following secondary infection with a different serotype. The phenomenon of immune enhancement has complicated vaccine development and likely explains the poor long-term safety profile of a recently licenced dengue vaccine. Therefore, alternative vaccine strategies should be considered. This review summarises studies dissecting the adaptive immune responses to dengue virus infection and (experimental) vaccination. In particular, we discuss the roles of (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.